Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Adjusted earnings of $2.17 a share topped the $2.02 analysts were anticipating, according to FactSet. However, second-quarter ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON ...